SHPMY Quote, Financials, Valuation and Earnings

China Pharma Holding has a net margin of 1.58% compared to Shanghai Pharmaceuticals Holding's net margin of -101.61%. Shanghai Pharmaceuticals Holding's return on equity of 4.92% beat China Pharma Holding's return on equity of -66.27%.

Shanghai Pharmaceuticals Holding has a consensus price target of --, signalling downside risk potential of --. On the other hand China Pharma Holding has an analysts' consensus of -- which suggests that it could fall by --. Given that Shanghai Pharmaceuticals Holding has higher upside potential than China Pharma Holding, analysts believe Shanghai Pharmaceuticals Holding is more attractive than China Pharma Holding.

Shanghai Pharmaceuticals Holding has a beta of 0.610, which suggesting that the stock is 38.991% less volatile than S&P 500. In comparison China Pharma Holding has a beta of 0.605, suggesting its less volatile than the S&P 500 by 39.47%.

Shanghai Pharmaceuticals Holding has a quarterly dividend of $0.06 per share corresponding to a yield of 4.23%. China Pharma Holding offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Shanghai Pharmaceuticals Holding pays 105.66% of its earnings as a dividend. China Pharma Holding pays out -- of its earnings as a dividend.

Shanghai Pharmaceuticals Holding quarterly revenues are $9.8B, which are larger than China Pharma Holding quarterly revenues of $1.1M. Shanghai Pharmaceuticals Holding's net income of $155.3M is higher than China Pharma Holding's net income of -$1.1M. Notably, Shanghai Pharmaceuticals Holding's price-to-earnings ratio is 10.62x while China Pharma Holding's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Shanghai Pharmaceuticals Holding is 0.16x versus 0.75x for China Pharma Holding. Usually stocks with elevated PS ratios are considered overvalued.

Sinovac Biotech has a net margin of 1.58% compared to Shanghai Pharmaceuticals Holding's net margin of --. Shanghai Pharmaceuticals Holding's return on equity of 4.92% beat Sinovac Biotech's return on equity of -1.05%.

Shanghai Pharmaceuticals Holding has a consensus price target of --, signalling downside risk potential of --. On the other hand Sinovac Biotech has an analysts' consensus of -- which suggests that it could fall by --. Given that Shanghai Pharmaceuticals Holding has higher upside potential than Sinovac Biotech, analysts believe Shanghai Pharmaceuticals Holding is more attractive than Sinovac Biotech.

Shanghai Pharmaceuticals Holding has a beta of 0.610, which suggesting that the stock is 38.991% less volatile than S&P 500. In comparison Sinovac Biotech has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Shanghai Pharmaceuticals Holding has a quarterly dividend of $0.06 per share corresponding to a yield of 4.23%. Sinovac Biotech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Shanghai Pharmaceuticals Holding pays 105.66% of its earnings as a dividend. Sinovac Biotech pays out -328.35% of its earnings as a dividend.

Shanghai Pharmaceuticals Holding quarterly revenues are $9.8B, which are larger than Sinovac Biotech quarterly revenues of --. Shanghai Pharmaceuticals Holding's net income of $155.3M is higher than Sinovac Biotech's net income of --. Notably, Shanghai Pharmaceuticals Holding's price-to-earnings ratio is 10.62x while Sinovac Biotech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Shanghai Pharmaceuticals Holding is 0.16x versus 1.50x for Sinovac Biotech. Usually stocks with elevated PS ratios are considered overvalued.

Zai Lab has a net margin of 1.58% compared to Shanghai Pharmaceuticals Holding's net margin of -40.75%. Shanghai Pharmaceuticals Holding's return on equity of 4.92% beat Zai Lab's return on equity of -35.53%.

Shanghai Pharmaceuticals Holding has a consensus price target of --, signalling downside risk potential of --. On the other hand Zai Lab has an analysts' consensus of -- which suggests that it could grow by 106.19%. Given that Zai Lab has higher upside potential than Shanghai Pharmaceuticals Holding, analysts believe Zai Lab is more attractive than Shanghai Pharmaceuticals Holding.

Shanghai Pharmaceuticals Holding has a beta of 0.610, which suggesting that the stock is 38.991% less volatile than S&P 500. In comparison Zai Lab has a beta of 1.003, suggesting its more volatile than the S&P 500 by 0.26999999999999%.

Shanghai Pharmaceuticals Holding has a quarterly dividend of $0.06 per share corresponding to a yield of 4.23%. Zai Lab offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Shanghai Pharmaceuticals Holding pays 105.66% of its earnings as a dividend. Zai Lab pays out -- of its earnings as a dividend.

Shanghai Pharmaceuticals Holding quarterly revenues are $9.8B, which are larger than Zai Lab quarterly revenues of $102.3M. Shanghai Pharmaceuticals Holding's net income of $155.3M is higher than Zai Lab's net income of -$41.7M. Notably, Shanghai Pharmaceuticals Holding's price-to-earnings ratio is 10.62x while Zai Lab's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Shanghai Pharmaceuticals Holding is 0.16x versus 6.97x for Zai Lab. Usually stocks with elevated PS ratios are considered overvalued.